Drug Combination Details
| General Information of the Combination (ID: C30853) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Liraglutide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Diminished ovarian reserve
[ICD-11: 5A80]
|
Phase 4 | [1] | ||
|
Atherosclerosis
[ICD-11: BD40]
|
Investigative | [2] | |||
|
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
liraglutide in combination with metformin has a synergistic anti-tumor effect on the pancreatic cancer cells, which may be at least partly due to activation of AMPK signaling. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | PRKAA2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HUVEC-C | CVCL_2959 | Healthy | Homo sapiens | ||
| In-vivo Model | High fat diet (HFD)-fed ApoE-/- mice were used in this study. | |||||
| Experimental
Result(s) |
Combination of metformin and liraglutide has synergistic protective effects on endothelial function. | |||||
